Sukyong Yoon

Mr. Sukyong Yoon

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SYSukyong Yoon
Sukyong Yoon
BJByung-Hak Jin
Byung-Hak Jin
CKChoon Ok Kim
Choon Ok Kim
KPKyungsoo Park
Kyungsoo Park
MPMin Soo Park
Min Soo Park
DCDongwoo Chae
Dongwoo Chae
Bepotastine, a second-generation antihistamine for allergic rhinitis and urticaria, is widely used in all age groups but lacks appropriate dosing guidelines for pediatric patients, leading to off-label prescriptions. We conducted this study to propose an optimal dosing regimen for pediatric patients based on population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models using data from two previous trials. A popPK model was built using NONMEM software. A one-compartment model with first-order absorption and absorption lag time described our data well, with body weight incorporated as the only covariate. A PBPK model was developed using PK-Sim software version 10, and the model well predicted the drug concentrations obtained from pediatric patients. Furthermore, the final PBPK model showed good concordance with the known properties of bepotastine. Appropriate pediatric doses for different weight and age groups were proposed based on the simulations. Discrepancies in recommended doses from the two models were likely due to the incorporation of age-dependent physiological factors in the PBPK model. In conclusion, our study is the first to suggest an optimal oral dosing regimen of bepotastine in pediatric patients using both approaches. This is expected to foster safer and more productive use of the drug.

1 January 2020 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HPHyeonsoo Park
Hyeonsoo Park
CKChoon Ok Kim
Choon Ok Kim
MKMikyung Kim
Mikyung Kim
YLYeji Lim
Yeji Lim
WLWoo yul Lee
Woo yul Lee
MPMin Soo Park
Min Soo Park
Park H, et al. Transl Clin Pharmacol. 2020 Sep;28:e16. /Synapse/10.12793/tcp.2020.28.e16

1 January 2020 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
WLWoo yul Lee
Woo yul Lee
EOEunSil Oh
EunSil Oh
MCMengqi Cui
Mengqi Cui
CKChoon Ok Kim
Choon Ok Kim
YLYeji Lim
Yeji Lim
THTaegon Hong
Taegon Hong
Lee WY, et al. Transl Clin Pharmacol. 2020 Mar;28:e5. /Synapse/10.12793/tcp.2020.28.e5

1 September 2021 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SYSukyong Yoon
Sukyong Yoon
EOEunSil Oh
EunSil Oh
MPMin Soo Park
Min Soo Park
SJSeong Bok Jang
Seong Bok Jang
HBHae Mi Byun
Hae Mi Byun
CKChoon Ok Kim
Choon Ok Kim
YH4808 is a novel potassium-competitive acid blocker developed for gastric acid-related disorders. Previous studies indicate its potential to improve symptoms of gastric acid-related disorders. The current study was aimed to find the optimal regimen of YH4808 for night time pH control. This study was performed in two parts. Each was a randomized, open-label, active-controlled, multiple-doses, two-treatment, two-period crossover study conducted in 20 healthy Korean volunteers. Subjects were randomly assigned to one of the four groups. The three groups received different dosage regimens of YH4808 (100 mg twice a day, 200 mg once a day, or 200 mg twice a day), and the fourth group received esomeprazole 40 mg twice a day. The pharmacokinetic parameters demonstrated that the systemic exposure of YH4808 increased in a dose-proportional manner. The difference in the proportion of time above pH 4 over 24 h from the baseline was the greatest in the group receiving YH4808 200 mg twice a day. The values of the area under the effect curve at night time (12 A.M.-7 A.M.) were higher in all YH4808 groups than in the esomeprazole group. However, the differences among the YH4808 groups were not statistically significant (p > 0.05). YH4808 exhibited potential for better pH control during the night in comparison to esomeprazole. The optimal regimen for night time pH control among all the YH4808 regimens was 200 mg twice a day.